All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
4 Stocks to Buy for Attractive Earnings Acceleration
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
4 Must-Buy Stocks for Remarkable Earnings Acceleration
This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.